Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity

Next Previous
X
Search
Trial Profile

Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms STEP 1
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 24 Aug 2023 Results assessing effect of semaglutide on 10-year type 2 diabetes risk in adults with overweight or obesity in STEP1 & STEP 5 studies, published in the Obesity (Silver Spring, Md.)
    • 24 Jun 2023 Results of pooled analysis from STEP 1 and STEP 2 presented at the European Association for the Study of the Liver Congress 2023
    • 16 Jan 2023 Results of exploratory analyses from STEP 1 and 4 ; evaluating the effects of once-weekly subcutaneous semaglutide 2.4 mg on cardiometabolic risk factors in people with overweight/obesity without diabetes, published in the Diabetes, Obesity and Metabolism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top